These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12412480)

  • 1. Generation of recombinant immunotoxins for specific targeting of tumor-related peptides presented by MHC molecules.
    Cohen CJ; Denkberg G; Segal D; Reiter Y
    Methods Mol Biol; 2003; 207():269-82. PubMed ID: 12412480
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant single-chain and disulfide-stabilized Fv immunotoxins for cancer therapy.
    Niv R; Segal D; Reiter Y
    Methods Mol Biol; 2003; 207():255-68. PubMed ID: 12412479
    [No Abstract]   [Full Text] [Related]  

  • 3. Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy.
    Hombach A; Heuser C; Abken H
    Methods Mol Biol; 2003; 207():365-81. PubMed ID: 12412486
    [No Abstract]   [Full Text] [Related]  

  • 4. Present Yourself! By MHC Class I and MHC Class II Molecules.
    Rock KL; Reits E; Neefjes J
    Trends Immunol; 2016 Nov; 37(11):724-737. PubMed ID: 27614798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotoxin therapy of cancer.
    Pastan I; Hassan R; Fitzgerald DJ; Kreitman RJ
    Nat Rev Cancer; 2006 Jul; 6(7):559-65. PubMed ID: 16794638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant immunotoxins in targeted cancer cell therapy.
    Reiter Y
    Adv Cancer Res; 2001; 81():93-124. PubMed ID: 11430597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
    Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
    Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of bispecific tandem diabodies for tumor therapy.
    Kipriyanov SM
    Methods Mol Biol; 2003; 207():323-33. PubMed ID: 12412483
    [No Abstract]   [Full Text] [Related]  

  • 9. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
    Reiter Y; Brinkmann U; Lee B; Pastan I
    Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural implications for the design of molecular vaccines.
    Apostolopoulos V; Yu M; McKenzie IF; Wilson IA
    Curr Opin Mol Ther; 2000 Feb; 2(1):29-36. PubMed ID: 11249650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.
    Mazor R; King EM; Pastan I
    Am J Pathol; 2018 Aug; 188(8):1736-1743. PubMed ID: 29870741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.
    Ostrand-Rosenberg S; Garcia EP; Roby CA; Clements VK
    Semin Cancer Biol; 1991 Oct; 2(5):311-9. PubMed ID: 1773047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy: natural versus synthetic peptides.
    Protti MP; Bellone M
    Immunol Today; 1998 Feb; 19(2):98. PubMed ID: 9509766
    [No Abstract]   [Full Text] [Related]  

  • 15. On the trail of empty MHC class-I.
    Theodossis A
    Mol Immunol; 2013 Sep; 55(2):131-4. PubMed ID: 23141301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Random peptide libraries. A tool for analyzing peptide specificity of major histocompatibility complex class I molecules.
    Stevens J; Butcher GW
    Methods Mol Biol; 2001; 156():187-99. PubMed ID: 11068760
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytosolic targeting of hen egg lysozyme gives rise to a short-lived protein presented by class I but not class II major histocompatibility complex molecules.
    Calin-Laurens V; Forquet F; Mottez E; Kanellopoulos J; Godeau F; Kourilsky P; Gerlier D; Rabourdin-Combe C
    Eur J Immunol; 1991 Mar; 21(3):761-9. PubMed ID: 2009914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
    Denkberg G; Reiter Y
    Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of MHC class I-deficient tumors.
    Reiniš M
    Future Oncol; 2010 Oct; 6(10):1577-89. PubMed ID: 21062157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis.
    Reiter Y; Pastan I
    Trends Biotechnol; 1998 Dec; 16(12):513-20. PubMed ID: 9881483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.